Intellectual property isBD tradingThe core target in the market. In transactions worth hundreds of millions or even billions of dollars, IP serves as the pricing anchor—buyers
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to China Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into credible
· US Patent and Trademark Office's Latest Research on IP-Intensive Industries: IP Rights Drive Continuous Growth in GDP and Employment · Saudi Arabia Launches Digital Platform
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to China Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into credible
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to China Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into credible
Introduction: This week, 11 biopharmaceutical companies completed financing, covering AI pharmaceuticals, neuromodulation, in vivo CAR-T, molecular diagnostics, and other sectors. Anlan Dejian has invested nearly 100
Introduction So far, the drug patent linkage system has profoundly changed the competitive landscape of China’s pharmaceutical market—it directly determines when generics can be launched, whether
From scientific potential to “collaborative assets,” the scientific, intellectual property, and cross-border BD evaluation framework for inhaled antifibrotic projects < a set of public information evaluation methods targeting Chinese
· Baoji's Patent Authorization Achievements in the First Half of the Year · Fujian's Longyan: Introduces Guidelines for "Pay-after-Use" Patent Model · Shaanxi Shangnan County Market
In the pharmaceutical field, whether an invention can obtain a patent or remain valid depends not only on the technical quality of the invention itself but